UPDATE 1-Lilly’s bowel disease drug gets US FDA nod for treatment in adults

Eli Lilly and Co said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease. The drug, which will be available in the United States in coming weeks and sold under brand name Omvoh, is among Lilly's potential growth drivers for this decade alongside tirzepatide for obesity, lebrikizumab for atopic dermatitis or eczema and pirtobrutinib for cancer. The agency's decision will help Lilly enter a sector, where drugs from rivals such as Abbvie Inc, Pfizer Inc and Johnson & Johnson are already jostling for a share of the multi-billion dollar market.